Lipid metabolism disorder in diabetic kidney disease

Front Endocrinol (Lausanne). 2024 Apr 29:15:1336402. doi: 10.3389/fendo.2024.1336402. eCollection 2024.

Abstract

Diabetic kidney disease (DKD), a significant complication associated with diabetes mellitus, presents limited treatment options. The progression of DKD is marked by substantial lipid disturbances, including alterations in triglycerides, cholesterol, sphingolipids, phospholipids, lipid droplets, and bile acids (BAs). Altered lipid metabolism serves as a crucial pathogenic mechanism in DKD, potentially intertwined with cellular ferroptosis, lipophagy, lipid metabolism reprogramming, and immune modulation of gut microbiota (thus impacting the liver-kidney axis). The elucidation of these mechanisms opens new potential therapeutic pathways for DKD management. This research explores the link between lipid metabolism disruptions and DKD onset.

Keywords: diabetic kidney disease; ferroptosis; gut microbiota; lipid metabolism; metabolic reprogramming; treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetic Nephropathies* / metabolism
  • Gastrointestinal Microbiome
  • Humans
  • Lipid Metabolism Disorders / complications
  • Lipid Metabolism Disorders / metabolism
  • Lipid Metabolism*

Grants and funding

This study was supported by The National Natural Youth Science Foundation of China (No. 82004196), National Natural Science Foundation of China (Grant No. 82374382), and Chinese Medicine Inheritance and Innovation Talent Project-Leading Talent Support Program of National Traditional Chinese Medicine (Grant No. 2018, No. 12), Tongzhou District to promote the medical and health industry development project(Grant No.JX2023YJ025).